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matched siblings in all instances. The median number of CD34
cells infused was 5.2  106/kg in both groups. All patients received
cyclosporine and methotrexate as GvHD prophylaxis. Eleven pa-
tients (68%) were transplanted as an outpatient. Results: The
range of follow-up from date of transplantation was 4–60 months.
All patients showed myeloid engraftment (neutrophils 0.5 
109/l) after a median of 15 days, and platelet recovery 20  109/l
was achieved after a median of 13 days. Acute GVHD was observed
in 7 (43.7%) patients and chronic GVHD in 8 (50%) patients,
without signiﬁcant differences in both groups. The relapse inci-
dence and mortality for the 9 patients who were transplanted in
FCR was 22%, and for patients transplanted in SCR was 85%.
Death occurred because of relapse in all cases. Conclusions: Our
data show that reduced-intensity conditioning and allogeneic
HSCT can induce stable remission in AML patients transplanted
in FCR. More studies are needed to determine the role of non-
myeloablative conditioning and transplantation in patients with
refractory or relapsing AML.
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HEMATOPOIETIC CELL TRANSPLANTATION FROM UNRELATED AND
RELATED DONORS AFTER A FLUDARABINE-ALKYLATOR-BASED REGI-
MEN IS A REASONABLE TREATMENT OPTION FOR OLDER PATIENTS
(>60 YEARS) WITH ACTIVE HEMATOLOGIC MALIGNANCIES
Finke, J.; Spyridonidis, A.; Ihorst, G.; Gruellich, C.; Zeiser, R.; Bertz,
H. Department of Hematology & Oncology, Freiburg University Medical
Hospital, Freiburg, Germany.
The upper age limit for allogeneic hematopoietic cell transplan-
tation (aHCT) used to be in the range of 50 to 55 years, well below
the age with the highest incidence of myeloid malignancies. Here
we present retrospective data on 69 consecutive patients (pts) older
than 60 years of age (median 64; range 60–74) transplanted from a
matched sibling (n20) or unrelated (n49) donor after condi-
tioning with a uniform, dose-adapted, myeloablative conditioning
regimen consisting of ﬂudarabine 150 mg/m2, carmustine 300
mg/m2 and melphalan 110 mg/m2 (FBM). GvHD prophylaxis
consisted of cyclosporine A and mycophenolate mofetil with addi-
tional rabbit anti-T lymphocyte globulin (ATG) in the unrelated
setting. Apart from 5 pts. receiving marrow all other pts received
ﬁlgastrim mobilized peripheral blood grafts (PBHCT). Pts pre-
sented with CLL (3), follicular NHL (2), mantle cell NHL (2),
multiple myeloma (1), myeloproliferative syndrome (3), MDS-RA
(3) and AML or MDS-RAEB (n55). Apart from 3 pts in CR1 and
3 in CR2, all other had active disease, either refractory or un-
treated. Acute GvHD II° occurred in 10 related (50%) and 16
unrelated (45%) transplanted pts. In the related transplantations, 6
pts died due to TRM (30%) and 4 due to relapse (20%). Causes of
death were infections (4 pts), acute GvHD (1 pt) and infection in
the context of chronic GvHD (1 pt). In the unrelated transplanta-
tions, there were 8 deaths due to TRM (16%) and 6 due to relapse
(12%). Causes of death after unrelated aHCT were graft failure (1
pt), ARDS (1 pt), infections (4 pts), acute GvHD (1 pt) and
myocardial infarction (d 230 after aHCT, 1 pt). After a median
follow up of approx. 1 year (range 3–1778 days), the estimated
probability of overall survival was 46% and 61% for related and
unrelated transplantations, respectively. This difference was not
statistically signiﬁcant. We conclude, that aHCT using the dose-
adapted FBM protocol is a reasonable treatment option for pts
older than 60 years of age with high risk lympho-hematologic
malignancies. In contrast to previous reports from transplant reg-
istries, we found that aHCT from unrelated donors incorporating
in vivo ATG results in outcomes comparable to HCT from related
donors. We suggest that the lack of HLA identical relatives in
older pts should not discourage the transplant choice.
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DYSREGULATION OF THE 	
 T CELL REPERTOIRE IN PATIENTS WITH
ACUTE LEUKEMIA: IMPLICATIONS FOR CELLULAR IMMUNOTHERAPY
Lamb, L.S. University of Alabama at Birmingham, Birmingham, AL.
Introduction: Despite their relatively small numbers,  T
cells have signiﬁcant innate anti-tumor activity. This is princi-
pally due to their ability to respond, without prior exposure or
priming, to a broad array of stress-associated antigens com-
monly displayed on malignant cells. Our laboratory has shown
increased allogeneic  T cells to have a protective effect against
relapse in patients transplanted for leukemia, and that  T cells
are not associated with increased risk of graft versus host disease
in these patients. In order to gain insight into the nature of a
potential antileukemic effect of  T cells, we sought to deter-
mine if evidence existed for an autologous  T cell immune
response in pre-treatment leukemia patients. Methods: We ﬁrst
examined the  T cell receptor (TCR) phenotype and comple-
mentarity determining region 3 (CDR3) cDNA sequence from
17 leukemia patients and 3 healthy controls to determine the 
TCR repertoire and clonality. Following this, we cultured  T
cells from healthy ﬁrst degree relatives with the corresponding
patients’ primary leukemic blasts. We then examined  T cell
proliferation and TCR repertoire at weekly intervals and cyto-
toxicity to patient blasts after 3–4 weeks of culture and com-
pared these results with co-cultures of  T cells from healthy
volunteers and normal allogenic mononuclear cells (MNC).
Results: All patients and healthy volunteers had normal abso-
lute  T cell counts. In 15/17 patients, V1  T cells were
predominant, in contrast to V2 predominance in healthy
volunteers. V1 CDR3-region cDNA sequence analysis re-
vealed that leukemia patients exclusively used the J1 constant
region, with healthy controls showing both J1 and J2 use.
Two patients with APL showed signiﬁcant CDR3 conservation
as did one B-ALL and one T-ALL patient. When fresh alloge-
neic  T cells were cultured with primary patient blasts, V2
T cells were quickly deleted and V1 T cells proliferated and
in 4 instances were able to lyse primary blasts. Insigniﬁcant 
T cell proliferation was observed in cultures with normal MNC.
Conclusions: These ﬁndings point to a complex dysregulation
in the  T cell compartment in leukemia patients including
deletion of the V2 subtype in vitro and in vivo and a V1 T
cell response to leukemia in vivo. These ﬁndings suggest con-
sideration of allogeneic  T cell therapy as part of a compre-
hensive immunotherapeutic strategy for acute leukemia.
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GEMTUZUMAB-OZOGAMICIN (GO; MYLOTARG) AS PART OF CONSOL-
IDATION THERAPY FOR AML BEFORE AUTOGRAFT: LOW INCIDENCE
OF HEPATIC VENO-OCCLUSIVE DISEASE
Fernandez, H.F.1; Kim, H.T.2; Bennett, J.M.3; Dewald, G.4; Talllman,
M.S.5; Lazarus, H.M.6 1. University of Miami, Miami, FL; 2. Dana
Farber Cancer Institute, Boston, MA; 3. University of Rochester, Roch-
ester, NY; 4. Mayo Clinic, Rochester, MN; 5. Northwestern University,
Chicago, IL; 6. University Hospitals of Cleveland, Cleveland, OH.
Background: Gemtuzumab-Ozogamicin (GO) has been used
successfully in induction therapy for de novo acute myeloid
leukemia (AML). Several reports note a high incidence of he-
patic veno-occlusive disease (VOD) when given within 115 days
of transplant, particularly in allogeneic transplant recipients.
Data are limited in the autologous transplant setting. Methods:
In an ongoing ECOG (E1900) study for de novo AML in patients
less than 61 years of age, GO was given as consolidation therapy
to 23 patients median (range) age 51 (21–59) years who achieved
complete remission after induction with cytarabine 100 mg/m2/
day CI over 7 days plus daunorubicin 45–90 mg/m2/day for 3
days. Two separate consolidations then were given using cytar-
abine 3 g/m2  6 doses. Upon recovery from the second cycle,
patients were given one dose of GO 6 mg/m2. Upon recovery of
blood counts after GO, patients underwent an autotransplant
conditioning regimen of IV busulfan 0.8 mg/kg  16 doses and
cyclophosphamide 60 mg/kg  2 doses with autologous blood
stem cell support. Results: One patient developed VOD after
the administration of GO but fully recovered without further
sequelae. The remaining 22 patients have proceeded to trans-
plant. All have engrafted after their procedure with no patient
experiencing VOD within 100 days post-transplant. Conclu-
sion: GO is a safe consolidation approach in younger AML
patients with less than 5% developing VOD with its use when
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followed with a standard autologous transplant approach. Long-
term efﬁcacy of this therapy and its impact upon disease-free
and overall survival still has not been established, but is the
subject of this ongoing trial.
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PRETRANSPLANT CONDITIONING WITH IV BUSULFAN (BU) AND FLU-
DARABINE (FLU) AS ALTERNATIVE TO BU AND CYCLOPHOSPHAMIDE
(CY)—A SAFE, MYELOABLATIVE REGIMEN WITH HIGH ANTILEUKEMIC
EFFICACY IN AML/MDS
de Lima, M.1; Couriel, D.1; Shahjahan, M.1; Alamo, J.1; Madden, T.1;
Thapar, N.1; Russell, J.2; Anderlini, P.1; Giralt, S.1; Shpall, E.1; Jones,
R.1; Champlin, R.1; Andersson, B.1 1. The University of Texas M.D.
Anderson Cancer Center, Houston, TX; 2. Alberta BMT Program,
Canada
Background: As an alternative to Cy in combination with IV Bu
as preparation for allogeneic stem cell transplantation (AlloSCT),
we proposed that Flu, which does not depend on the hepatic
GSH/GST pathways for its metabolism, would yield improved
safety, yet retained antileukemic efﬁcacy. We have now compared
a series of patients receiving pretransplant conditioning therapy
with IV Bu-Flu to that of a previous group conditioned with the IV
BuCy2 regimen.Methods: Flu 40 mg/m2 IV was given once daily,
each dose followed immediately by Bu 130 mg/m2 IV over 3 hr
(days 6 till 3). In the IV BuCy2 Bu was given at 0.8 mg/kg over
2 hr every 6 hr for 16 doses (days 7 till 4), followed by Cy 60
mg/kg on days 3 and 2. Patients with an unrelated (MUD) or
mismatched donor received ATG on days 3 to 1. Graft-versus-
host disease (GVHD) prophylaxis was based on tacrolimus and
mini-methotrexate. Results: Median age was 46 (19–66) years
(Bu-Flu group, n128 patients) and 39 (13–64) years (BuCy
group, n72 patients), respectively. At the time of transplant 45%
and 46% patients in each group were in CR1-3, the remainder had
active disease. Cytogenetic risk category group was poor or inter-
mediate in 88% of the patients in the IV Bu-Flu and in 82% of the
BuCy2 group. Donors were HLA-identical siblings (SIBS) in 53%,
and 73%, MUDs in 39% and 15%, others in 8% and 12%,
respectively in the Bu-Flu and BuCy2 groups. Median follow-up
for patients alive (October 2004) was 16.5 mos (6–40; n78) for
the IV Bu-Flu group, and 47 mos (24–76; n26) for BuCy pa-
tients. 100-day treatment-related mortality (TRM) was for SIB/
MUD 2.7/2% after IV Bu-Flu, and 7/9% in the BuCy2 group,
respectively. Overall, one-year TRM was for 7% after Bu-Flu and
18% after BuCy2. The overall aGvHD rates were 42% and 45%.
The 2-year overall survival (OS) was 50% for the whole IV Bu-Flu
group, 42% after IV BuCy2. For patients transplanted in CR the
2-yr OS and event-free survival were 69% and 68% after IV
Bu-Flu, and 48% and 41% in the IV BuCy2 (p0.03). Table shows
pharmacokinetics data. Conclusions: IV Bu-Flu is a safe, reduced
toxicity myeloablative-conditioning regimen when used in the
AML/MDS patient population. Its antileukemic efﬁcacy appears to
be at least comparable to that experienced with the IV BuCy2
regimen. Our data demonstrate that the IV Bu-Flu regimen should
be considered as a new standard for myeloablative conditioning
therapy for alloSCT in AML/MDS.
Parameter (units)
Q Day IV Bu
(CV%)
Q 6 H IV Bu
(CV%)
Cmax (ug/ml) 3.6 (14) 1.2 (19.7)
Vd (L/m2) 22.56 (20.2) 22.65 (21.3)
Clearance (ml/min/m2) 109.3 (26) 116.4 (24)
T1/2 (hours) 2.73 (27.5) 2.91 (25)
AUC (M  min) 4,925 (25.5) 1,292 (25)
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IDENTIFICATION OF NOVEL WT1 EPITOPES BY SENSITIZATION OF
HUMAN T CELLS WITH OVERLAPPING PENTADECAPEPTIDES SPAN-
NING THE WT1 PROTEIN FOR THE TARGETED ADOPTIVE IMMUNO-
THERAPY OF LEUKEMIA
Doubrovina, E.; Dupont, J.; Trivedi, D.; O’Reilly, R.J. Memorial
Sloan-Kettering Cancer Center, New York, NY
The oncofetal protein, WT1, is differentially expressed in 60–
80% of acute leukemias and CML. Previously, four peptide
epitopes presented by HLA-A0201 or HLA-A2402 have been
identiﬁed. We hypothesized that other epitopes presented on the
same or different HLA alleles may be key players in WT1 speciﬁc
anti-tumor T cell response. We used a pool of 15-mers with 10
amino acid overlaps spanning the full sequence of WT1, loaded on
autologous monocytes-derived dendritic cells or EBV-transformed
BLCL to sensitize and raise T cell lines from 9 normal donors
expressing or not expressing HLA-A0201 or HLA-A2402. Speciﬁc
15-mers eliciting responses were identiﬁed by quantitating IFN
CD8 or CD4 T cell responses to secondary stimulation with
15-mer subpools organized in a mapping grid with single overlaps.
Cytolytic responses against targets loaded with the identiﬁed stim-
ulating 15-mer and sharing single HLA class I or II alleles permit-
ted identiﬁcation of restricting HLA alleles in standard 51Cr re-
lease assay. Individuals inheriting HLA-A0201 have generated
CD8 T cells in response to the complete pool which are selec-
tively reactive against single 15-mers containing the known im-
munogen 252–260RMFPNAPYL. However, in certain donors,
responses to other 15-mers 28 and 33, containing heretofore un-
reported epitopes 136–144ALLPAVPSL and 163–171VLDFAP-
PGA accordingly have been dominant and restricted by the HLA-
A0201 allele. By mapping responses of T cells sensitized with the
complete pool, deﬁning the presenting HLA alleles and delineating
immunogenic sequences within speciﬁc 15-mers, additional novel
epitopes presented by HLA-B0801, DRB10301 and DRB10402 for
both CD8 and CD4 WT1 speciﬁc T cells have also been
deﬁned. CTL generated by this approach also lysed both peptide-
loaded targets as well as primary WT1 leukemic cells expressing
the restricting HLA allele. Thus, sensitization with pools of over-
lapping synthetic 15-mers spanning WT1has made possible iden-
tiﬁcation of several new immunodominant HLA class I and II
WT1 epitopes which selectively stimulate both CD8 and CD4
WT1-speciﬁc T cell lines that are leukemocidal and therefore of
possible use for extending the potential of WT1 speciﬁc T cells for
adoptive immunotherapy to patients with WT1 tumors not ex-
pressing HLA-A0201 or A2402.
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